Lataa...
Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada
PURPOSE: High‐strength opioid formulations were delisted (removed) from Ontario's public drug formulary in January 2017, except for palliative patients. We evaluated the impact of this policy on opioid utilization and dosing. METHODS: We conducted a longitudinal study among patients receiving p...
Tallennettuna:
| Julkaisussa: | Pharmacoepidemiol Drug Saf |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6518867/ https://ncbi.nlm.nih.gov/pubmed/30873707 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pds.4764 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|